objective(s) the sst-i polymorphic site on the 3' untranslated region of the apo ciii gene, has been previously reported to be associated with hypertriglyceridemia. the aim of the present study was to explore the association between sst-i polymorphism with plasma lipid and lipoprotein levels in hyperlipidemic (hlp) patients from semnan province, iran. materials and methods genomic dna was ...

background: calcineurin inhibitors (cni) have significantly reduced the incidence of acute rejection. nephrotoxicity however may contribute to long-term allograft dysfunction. mycophenolate mofetil (mmf) may allow cyclosporine (csa) dose reduction without increasing the risk of rejection. methods: in seventy-eight living unrelated kidney transplant patients with renal dysfunction, we studied th...

cardiovascular diseases with an incidence of approximately 50% are the main causes of death in most advanced countries and an increasing trend in the developing world as well. the world health organization estimates that 12 million people per year worldwide die from cardiovascular diseases. cardiovascular diseases are becoming an increasing problem worldwide and hypercholesterolemia has been co...

background: metabolic syndrome is a risk factor for cardiovascular disease (cvd) and  type 2 diabetes. the most important strategy for the prevention and management of metabolic syndrome is lifestyle and nutritional changes. the aim of this review study was to survey the role of pistachio in metabolic syndrome. materials and methods: web of science databases and google scholar were searched usi...

Pharmacologic treatment of hyperlipidemia in conjunction with therapeutic lifestyle changes can be used for both primary and secondary prevention of cardiovascular disease. Statins have the most convincing data for primary prevention, especially for higher risk patients. Therefore, risk stratification is essential. Statin therapy is also recommended for secondary prevention in all patients with...

Partial ileal bypass (PIB) is a safe, effective, and lasting therapy for the reduction of lipids and lipoproteins in patients with hyperlipidemia. Following PIB, cireulating plasma and low-density lipoprotein (LDL) cholesterol fall markedly, while high-density lipoprotein (HDL) cholesterol rises. The average plasma cholesterol lowering is 25 % after diet, with a 40 % reduction in the LDL-choles...

Hyperilpidemia is common after renal transpiantation. In recent years, much progress has been made in understanding the causes and treatment of lipid abnormalities in renal transplant patients. Recently, short-term studies have shown that newer antilipemic agents appear to be safe and effective in freating hyperlipidemia in this population. Despite the absence of large, controlled clinical tria...

Background: Hyperlipidemia increases mortality and is common with kidney-disease. New-onset hyperlipidemia (NOHL) among patients wait-listed and after transplantation may impact costs and graft-survival of patients with kidney disease. Methods: Using the United States Renal Data System, we compared the costs to Medicare associated with or without NOHL in wait-listed patients in the second and f...